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Objective: Nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of advanced chronic liver disease. The progression of NAFLD,
including nonalcoholic steatohepatitis (NASH), has a strong genetic component, and the most robust contributor is the patatin-like phospholipase
domain-containing 3 (PNPLA3) rs738409 encoding the 148M protein sequence variant. We hypothesized that suppressing the expression of the
PNPLA3 148M mutant protein would exert a beneﬁcial effect on the entire spectrum of NAFLD.
Methods: We examined the effects of liver-targeted GalNAc3-conjugated antisense oligonucleotide (ASO)-mediated silencing of Pnpla3 in a
knock-in mouse model in which we introduced the human PNPLA3 I148M mutation.
Results: ASO-mediated silencing of Pnpla3 reduced liver steatosis (p¼ 0.038) in homozygous Pnpla3 148M/M knock-in mutant mice but not in
wild-type littermates fed a steatogenic high-sucrose diet. In mice fed a NASH-inducing diet, ASO-mediated silencing of Pnpla3 reduced liver
steatosis score and NAFLD activity score independent of the Pnpla3 genotype, while reductions in liver inﬂammation score (p ¼ 0.018) and
ﬁbrosis stage (p¼ 0.031) were observed only in the Pnpla3 knock-in 148M/M mutant mice. These responses were accompanied by reduced liver
levels of Mcp1 (p ¼ 0.026) and Timp2 (p ¼ 0.007) speciﬁcally in the mutant knock-in mice. This may reduce levels of chemokine attracting
inﬂammatory cells and increase the collagenolytic activity during tissue regeneration.
Conclusion: This study provides the ﬁrst evidence that a Pnpla3 ASO therapy can improve all features of NAFLD, including liver ﬁbrosis, and
suppress the expression of a strong innate genetic risk factor, Pnpla3 148M, which may open up a precision medicine approach in NASH.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In parallel with the global increase in obesity, nonalcoholic fatty liver
disease (NAFLD) is becoming the leading cause of chronic liver disease
and liver transplantation worldwide [1]. NAFLD is deﬁned as excess
liver fat accumulation greater than 5% induced by causes other than
alcohol intake. NAFLD progresses to liver inﬂammation (nonalcoholic
steatohepatitis, NASH) and ﬁbrosis in a variable proportion of in-
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medical need in patients with NAFLD and NASH is an effective treat-
ment to halt the progression and possibly reverse ﬁbrosis, which is the
main predictor of liver disease evolution [3,4].
Recently, we reported evidence suggesting that genetically deter-
mined hepatic fat accumulation is a major driver of NASH and ﬁbrosis
[5]. Indeed, the progression of NAFLD has a strong genetic compo-
nent [6]. The rs738409 polymorphism in the patatin-like phospho-
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ALT alanine aminotransferase
ASK1 apoptosis signal-regulating kinase 1
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AST aspartate aminotransferase
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cEt constrained ethyl
Col1a1 collagen type I alpha 1 chain
Ctrl control
CVC cenicriviroc
FBS fetal bovine serum
FXR farnesoid X receptor
GalNAc3 triantennary N-acetylgalactosamine
GLP1 glucagon-like peptide-1
I isoleucine
Il interleukin
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H&E hematoxylin-eosin
HSD17B13 hydroxysteroid 17-beta dehydrogenase 13
Mac2 macrophage antigen 2
Mcp1 monocyte chemoattractant protein 1
MEM minimum essential medium
Mmp2 matrix metalloproteinase 2
MOE methoxyethylribose
MRI magnetic resonance imaging
MUFA monounsaturated fatty acid
NAFLD nonalcoholic fatty liver disease
M methionine
MUT mutant
NAS NAFLD activity score
NASH nonalcoholic steatohepatitis
OCA obeticholic acid
ORO Oil Red O
PDFF proton-density fat fraction
Plin2 perilipin 2
PNPLA3/Pnpla3 human/mouse patatin-like phospholipase domain-
containing 3
PUFA polyunsaturated fatty acid
Rplp0 ribosomal protein large P0
siRNA small interfering RNA
SFA saturated fatty acid
Tgfbr2 transforming growth factor, beta receptor 2
Timp tissue inhibitor of metalloproteinase
Tnfa tumor necrosis factor alpha
WT wild-type
Original Articlefrom isoleucine (I) to methionine (M) at position 148 of the protein)
exerts the largest effect on NAFLD progression identiﬁed to date
[7,8]. Furthermore, excess body fat ampliﬁes the genetic risk of
PNPLA3 148M on NAFLD [9e11]. The PNPLA3 protein has hydrolase
activity towards triglycerides and retinyl esters [12e15], promoting
lipid droplet remodeling in hepatocytes and hepatic stellate cells
[16,17]. The PNPLA3 148M mutant protein exhibits reduced enzy-
matic activity [12e17].
Pnpla3 148M mutant knock-in mice develop hepatic steatosis when
fed a steatogenic high-sucrose diet [18]. Similarly, mice over-
expressing the human 148M mutant form of PNPLA3 exhibit elevated
hepatic steatosis when fed a high-sucrose diet [19], whereas genetic
Pnpla3 deletion from birth does not inﬂuence hepatic fat accumulation
in mice [20,21]. The mechanism underlying the Pnpla3 148M
mutationemediated increase in hepatic steatosis does not seem to
involve increased lipogenesis or decreased fatty acid oxidation [15],
but it is partially due to very low-density lipoprotein retention, at least in
very obese individuals [15,16,22]. Moreover, the Pnpla3 148M mu-
tation alters the posttranslational modiﬁcation of Pnpla3. Wild-type
Pnpla3 is catabolized through proteasomal degradation via effective
ubiquitylation, whereas the Pnpla3 148M mutant protein escapes
ubiquitylation and subsequently accumulates on the surface of lipid
droplets, leading to impaired mobilization of triglycerides from the
hepatic lipid droplets [15]. Based on the results of these preclinical
studies, reduced expression of the PNPLA3 148M mutant protein may
exert beneﬁcial effects on NAFLD and potentially on NASH and liver
ﬁbrosis progression. This hypothesis is also supported by human
genetic data. Indeed, we have shown that another PNPLA3 genetic
variant (rs2294918), which is associated with lower hepatic PNPLA3
expression, mitigates the detrimental impact of the PNPLA3 148M
mutant protein [23]. Consistent with these data, a sequence variant in
the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene was
recently shown to be associated with lower PNPLA3 expression and
reduced the detrimental impact of the PNPLA3 148M protein [24].
Interestingly, the suppression of wild-type Pnpla3 expression with an50 MOLECULAR METABOLISM 22 (2019) 49e61  2019 The Authors. Published by Elsevier GmbH. Tantisense oligonucleotide (ASO) reduced the liver fat contents in rats
fed a high-fat diet by diminishing fatty acid esteriﬁcation [25]. This
ﬁnding is consistent with data reported by Kumari et al. showing that
Pnpla3 also promotes lipogenesis [26].
Taken together, we hypothesized that the suppressed expression of
the PNPLA3 148M mutant protein would exert a beneﬁcial effect on the
entire spectrum of NAFLD including ﬁbrosis. In this study, we tested
this hypothesis by silencing Pnpla3 in vivo using a liver-targeted ASO
treatment in Pnpla3 I148M knock-in mice fed steatogenic and NASH-
inducing diets.
2. MATERIALS AND METHODS
2.1. Screening and selection of murine Pnpla3 cEt 50-GalNAc3-
conjugated cEt ASOs
S-constrained ethyl (cEt)-modiﬁed 16-mer ASOs targeting the mouse
Pnpla3 gene were screened and tested for potency in primary mouse
embryonic cortical neurons via free uptake (data not shown). An
optimal potent mouse (50-TATTTTTGGTGTATCC-30) cEt ASO lead was
selected for all subsequent pharmacological studies. This mouse
Pnpla3 ASO was modiﬁed by 50-conjugation with triantennary N-
acetylgalactosamine (GalNAc3) to further enhance the liver cell tar-
geting in vivo following subcutaneous administration [27]. The speci-
ﬁcity of target knockdown was demonstrated using a chemistry-
matched scrambled control GalNAc3- conjugated ASO (50-GGCCAA-
TACGCCGTCA-30). The control GalNAc3-conjugated ASO did not affect
body weight-gain, liver weight, plasma alanine aminotransferase (ALT)
or liver triglyceride content when dosed at 10 mg/kg/week for six
weeks in mice fed a NASH-inducing diet (D09100301, Research Diets,
New Brunswick, NJ) as compared to saline vehicle controls
(Supporting Figure 1).
2.2. Animals
All animal experiments were performed with humane care and were
approved by the Gothenburg Ethics Committee for Experimentalhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Animals in Sweden. The holding facility has received full accreditation
from the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC).
The human PNPLA3 I148M mutation was introduced into the mouse
Pnpla3 gene by replacing the isoleucine codon with a methionine
codon in amino acid position 148 of the mouse Pnpla3 gene using
homologous recombination (Supporting Figure 2A and B) as described
in the Supporting Materials and Methods. Founders were backcrossed
with C57BL/6N females to generate heterozygous Pnpla3 148I/M mice.
Sequence-veriﬁed heterozygous Pnpla3 148I/M mice (Supporting
Figure 2C) were intercrossed to generate experimental homozygous
Pnpla3 148M/M and wild-type littermates (Pnpla3 148I/I) as control
mice for the dietary challenge and ASO pharmacology studies. All
experimental animals were veriﬁed to have the correct genotype using
PCR before the study began and veriﬁed again using PCR after
termination, as described in the Supporting Materials and Methods. A
few experimental animals were also veriﬁed by cDNA sequencing
(Supporting Figure 2D), as outlined in the Supporting Materials and
Methods. All animals were housed in transparent Makrolon cages with
aspen wood chip bedding and nesting material, and the temperature-
(21  1 C) and humidity (50  10%) of the holding facility were
controlled. The mice had free access to tap water and food and were
on a 12-h day/night cycle.
Female Pnpla3 148M/M (n ¼ 21) and wild-type littermates (n ¼ 19)
(6e8 weeks of age) were fed a high-sucrose diet (70% sucrose diet;
TD98090, Envigo, Huntingdon, UK) for 15 weeks. Female mice were
used in this experiment to replicate the established model by Smagris
et al. [18], who used female animals in their high-sucrose diet ex-
periments. In addition, in a pilot experiment, female mice accumulated
more triglycerides in the liver compared to male mice when fed this
diet (Supporting Figure 3A). In addition, female mice fed the high-
sucrose diet accumulated more liver triglycerides compared to mice
fed a regular chow diet containing (energy percentage) 12% fat, 62%
carbohydrates, and 26% protein, with a total energy content of 3 kcal/g
(R3; Lactamin, Kimstad, Sweden) (Supporting Figure 3B). After 5
weeks of feeding on the high-sucrose diet, liver lipid levels were
assessed using a magnetic resonance imaging (MRI)ederived marker,
proton-density fat fraction (PDFF), as described in the Supporting
Materials and Methods. The mice were then assigned to GalNAc3-
conjugated ASO study groups (n ¼ 9e12 animals/group) based on
randomized stratiﬁcation for body weight and liver lipid contents before
the treatment was initiated. During the last 8 weeks of the study,
groups of mice were dosed with either the control ASO or Pnpla3 ASO
(5 mg/kg/week administered by two subcutaneous injections per week
with saline as vehicle). After 6 weeks of ASO dosing, liver lipid levels
were again assessed using MRI. Before unfasted mice were eutha-
nized at 8:00e10:00 AM, the mice were metabolically synchronized
for 24 h by withdrawing the food from 8:00 AM to 8:00 PM and then
allowed free access to the food again from 8:00 PM to 8:00 AM. Mice
were euthanized with isoﬂurane (Forene, Abbot Scandinavia AB,
Sweden), blood was collected and plasma isolated, livers were
collected, and pieces (same position in the left lateral lobe for all mice)
were ﬁxed with 4% formaldehyde in PBS for histology or snap-frozen in
liquid N2 and stored at 80 C.
Male Pnpla3148 M/M mice (n¼ 17) and wild-type littermates (n¼ 17)
(6e8 weeks of age) were fed a diet high in fat (40%, containing 18%
trans-fat), carbohydrates (40%, containing 20% fructose) and
cholesterol (2%) (NASH diet; D09100301, Research Diets, New
Brunswick, NJ) [28e30] for 26 weeks. In a separate experiment, liver
Pnpla3 mRNA, triglyceride content as well as plasma ALT levels were
found to be elevated in wild-type male mice fed the NASH-inducingMOLECULAR METABOLISM 22 (2019) 49e61  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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Figure 4). The mice were assigned to GalNAc3-conjugated ASO
study groups (n¼ 8e9 mice/group) based on body weight, and during
the last 14 weeks, the mice were dosed with either the control ASO or
Pnpla3 ASO (5 mg/kg/week administered by two subcutaneous in-
jections per week with saline as vehicle). Before unfasted mice were
euthanized at 8:00e10:00 AM, the mice were metabolically syn-
chronized for 24 h as described above. Mice were euthanized with
isoﬂurane (Forene, Abbot Scandinavia AB, Sweden), blood was
collected and plasma isolated, livers were collected, and pieces (same
position in the left lateral lobe for all mice) were ﬁxed with 4%
formaldehyde in PBS for histology or snap-frozen in liquid N2 and
stored at 80 C.
2.3. Liver and plasma biochemistry
Non-anesthetized plasma glucose levels were measured in tail vein
blood using a portable glucometer (Accu-Chek mobile). Plasma in-
sulin levels were measured using a mouse/rat Insulin kit from Meso
Scale Discovery (K152BZC-1, Rockville Maryland USA). Liver triglyc-
eride and plasma triglyceride, ALT, aspartate aminotransferase (AST)
and haptoglobin levels were analyzed using an ABX Pentra 400 in-
strument (Horiba Medical, Irvine, California, USA), and liver hydroxy-
proline levels were measured with an ELISA, as outlined in the
Supporting Materials and Methods.
2.4. Liver histology
Liver lipid Oil Red O and immunohistochemical staining (Mac-2 and
Col1A1) of mouse liver sections are detailed in Supporting Materials
and Methods. Fibrosis and components of the NAFLD activity score
(NAS) were determined on terminal samples according to the methods
reported by Kleiner et al. [31]. All histological assessments were
performed by a pathologist who was blinded to the treatment.
2.5. RNA preparation and qPCR
Total RNA was isolated from cells using an RNeasy Mini Kit (Qiagen).
First-strand complementary DNA and real-time quantitative PCR an-
alyses were performed according to standard techniques, as outlined
in the Supporting Materials and Methods.
2.6. Hepatic lipid droplet isolation
Lipid droplets were puriﬁed from frozen livers by sucrose density
gradient ultracentrifugation as previously described [18] and as
described in Supporting Materials and Methods.
2.7. Immunoblot analyses
The membranes were incubated with commercial antibodies
(Supporting Table 1) except for the anti-Pnpla3 primary antibody
(1:500), which was kindly provided by the Helen Hobbs laboratory at
the University of Texas Southwestern Medical Center at Dallas, TX,
USA.
2.8. Lipidomic analysis on lipid droplets
Lipidomic analyses was carried out by mass spectrometry as
described in Supporting Materials and Methods.
2.9. Statistical analysis
Differences between groups were examined using 2-sided t-tests
(GraphPad Prism v. 7.04, GraphPad Software, CA). Data were log-
transformed before statistical analyses when appropriate (when data
were skewed). A p value less than 0.05 was considered signiﬁcant.
Data are presented as the means  standard errors of the meanscess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 51
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lyses. Differences between categorical variables deriving from liver
histology (Figure 3) were analyzed by binary logistic analyses.
3. RESULTS
3.1. Pnpla3 silencing speciﬁcally reduces liver steatosis in Pnpla3
mutant knock-in mice fed a high-sucrose diet
To drive hepatic lipogenesis and to evaluate the impact of Pnpla3
silencing on hepatic fat accumulation, homozygous Pnpla3 148M/M
(mutant) knock-in female mice and wild-type littermates were fed a
high-sucrose diet (70%) for 15 weeks. During the last 8 weeks of the
experiment, mice of the two genotypes were treated with GalNAc3-
conjugated Pnpla3 or GalNAc3-conjugated control ASOs. No differ-
ences in body weight gain, food intake (Figure 1A and B, Supporting
Figure 5A and B) or in ovarian white adipose tissue weight
(Supporting Figure 6A) were observed between the groups. In addition,
the Pnpla3 ASO treatment did not affect plasma glucose or insulin
levels (Supporting Figure 7A and B). Compared to the control ASO, the
Pnpla3 ASO treatment markedly reduced the hepatic expression of
Pnpla3 mRNA (98% reduction, p < 0.0001) and levels of Pnpla3
protein on lipid droplets in both Pnpla3 mutant knock-in and wild-type
mice (Figure 1C and D). The Pnpla3 ASO treatment did not affect the
white adipose tissue expression of Pnpla3 mRNA levels (Supporting
Figure 8A).
Six weeks of the Pnpla3 ASO treatment reduced liver lipid levels by
20% in Pnpla3 mutant knock-in mice, as measured by MRI (Figure 1F,
p ¼ 0.025, Supporting Figure 9). After 8 weeks of treatment, the
Pnpla3 mutant knock-in mice treated with the Pnpla3 ASO showed
reduced liver weights (Supporting Figure 10A), lower liver Oil Red O
staining of neutral lipids (Figure 1E), a 20% reduction (p ¼ 0.038) in
liver triglyceride content, as measured by biochemical analyses
(Figure 1F), while no changes in circulating plasma triglyceride levels
were observed (Figure 1G). Interestingly, the Pnpla3 ASO treatment did
not affect the liver weights (Supporting Figure 10B), lipid level or liver
triglyceride content in the wild-type mice (Figure 1HeJ, Supporting
Figure 9). Pnpla3 mutant knock-in mice treated with the control ASO
had 30% higher liver triglyceride content than the wild-type mice
treated with the control ASO (Pnpla3mutant knock-in mice ¼ 5.7 
0.4 g/100 g liver, wild-type mice ¼ 4.4  0.5 g/100 g liver,
p ¼ 0.046).
Thus, in a high-sucrose diet model of moderate hepatic steatosis, the
Pnpla3 ASO treatment reduces the liver fat content in Pnpla3 mutant
knock-in mice but not in wild-type littermates.
3.2. Pnpla3 silencing reduces liver inﬂammation and ﬁbrosis
speciﬁcally in the Pnpla3 mutant knock-in mice fed a NASH-
inducing diet
Next, we tested the hypothesis that Pnpla3 silencing would reduce not
only the liver fat content but also liver inﬂammation and ﬁbrosis in a
mouse model of diet-induced NASH. Male Pnpla3 mutant knock-in
(n ¼ 17) and wild-type littermate (n ¼ 17) mice were fed a NASH-
inducing diet for 26 weeks. During the last 14 weeks of the experi-
ment, mice of both genotypes were treated with a GalNAc3-conjugated
Pnpla3 or GalNAc3-conjugated control ASO. No differences in body
weight gain, food intake (Figure 2A and B, Supporting Figure 5C and
D), or in epididymal white adipose tissue weight (Supporting
Figure 6B) were observed between the groups. In addition, the
Pnpla3 ASO treatment did not affect plasma glucose or insulin levels
(Supporting Figure 7C and D). Compared to the control ASO, the Pnpla3
ASO treatment markedly reduced (97%, p < 0.0001) hepatic52 MOLECULAR METABOLISM 22 (2019) 49e61  2019 The Authors. Published by Elsevier GmbH. Texpression of the Pnpla3 mRNA and consistently reduced levels of the
Pnpla3 protein on lipid droplets in both Pnpla3 mutant knock-in and
wild-type mice (Figure 2C and D). Using the NASH diet with a longer
treatment period than in the sucrose diet study (14 weeks vs 8 weeks,
respectively), the Pnpla3 ASO treatment also reduced the white adi-
pose tissue expression of Pnpla3 mRNA levels (Supporting Figure 8B).
The Pnpla3 ASO treatment reduced plasma ALT levels in mice of both
genotypes (Pnpla3mutant knock-in p¼ 0.0006, wild-type p¼ 0.018),
while plasma AST was unchanged (Figure 2E and F). The Pnpla3 ASO
treatment reduced liver weights only in the Pnpla3 mutant knock-in
mice (Supporting Figure 10CeD), triglyceride contents in both
Pnpla3 mutant knock-in (p ¼ 0.002) and wild-type mice (p ¼ 0.004),
while no changes in circulating plasma triglyceride levels were
observed (Figure 2E and F). Thus, in severe steatosis, silencing of
Pnpla3 expression in the liver reduces severe steatosis, regardless of
the genetic background.
Overall, the genotype had no signiﬁcant effect on liver damage
assessed by histology. However, the Pnpla3 ASO treatment improved
the liver steatosis score (p ¼ 0.007), lobular inﬂammation score
(p ¼ 0.018), NAFLD activity score (NAS) (p ¼ 0.0003), and ﬁbrosis
stage (p ¼ 0.031) in Pnpla3 mutant knock-in mice (Figure 3A) while
only liver steatosis score (p ¼ 0.003) and NAS (p ¼ 0.036) were
improved in the wild-type mice (Figure 3B). Hepatocellular ballooning
degeneration was not found in any of the livers. This is an expected
caveat with preclinical rodent NASH models in relation to human NASH
and in line with another study using the same NASH diet feeding length
in mice [30].
3.3. Pnpla3 silencing reduces de novo lipogenesis and palmitoleic
acid in Pnpla3 mutant knock-in and wild-type mice fed a NASH-
inducing diet
The Pnpla3 ASO treatment reduced the liver Oil Red O staining of neutral
lipids in both Pnpla3mutant knock-in and wild-type mice (Figure 4A). The
Pnpla3 ASO treatment reduced the mRNA expression of lipogenic genes,
such as acetyl-CoA carboxylase 1 (Acc1) and stearoyl-CoA desaturase 1
(Scd1) in both genotypes (Figure 4B and C), suggesting that hepatic
lipogenesis was reduced. Next, we examined the lipid composition of
puriﬁed lipid droplets from the liver. Pnpla3 ASO treatment decreased the
relative amount of monounsaturated fatty acids (MUFAs, p¼ 6.1 105
and 7.6 106 in the mutant and wild-type, respectively) and increased
polyunsaturated fatty acids (PUFAs, p ¼ 1.2  104 and 1.3  105 in
the mutant and wild-type, respectively) irrespective of the genotype
(Figure 4D and E, Table 1, Supporting Table 2). Speciﬁcally, the reduction
in MUFAs was stronger for the palmitoleic acid (16:1), 36%
(p ¼ 2.4  104) and 30% (1.0  109) reduction for the mutant and
wild-type, respectively as compared with the oleic acid where the
reduction was only 2% (p ¼ 0.034) and 5% (p ¼ 0.001) for the mutant
and wild-type, respectively.
3.4. Pnpla3 silencing reduces protein levels of haptoglobin, Mcp1
and Timp2 speciﬁcally in the Pnpla3 mutant knock-in mice fed a
NASH-inducing diet
The Pnpla3 ASO treatment reduced plasma haptoglobin levels
(p ¼ 0.0005) and the liver macrophage content (p ¼ 0.047) in Pnpla3
mutant knock-in mice but not in the wild-type littermates (Figure 5Ae
C), suggesting that Pnpla3 suppression speciﬁcally reduced liver
inﬂammation in the mutant mice. Pnpla3 ASO treatment speciﬁcally
reduced the liver Mcp1 (Figure 5D) protein levels in Pnpla3 mutant
knock-in mice but not in wild-type mice. Pnpla3 ASO treatment did not
change the liver protein expression levels of Il1b (Figure 5E), Il6
(Figure 5F), Tnfa (Figure 5G), or aSma (Figure 5H) in either genotype.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: The Pnpla3 ASO treatment reduced liver Pnpla3 mRNA and protein levels in both Pnpla3 mutant knock-in mice and wild-type littermates fed a high-sucrose
diet but reduced hepatic triglyceride content only in mutant mice. A total of 21 female homozygous Pnpla3 148M/M knock-in mice and 19 wild-type littermates were fed a
high-sucrose diet for 15 weeks. After 7 weeks of feeding on the high-sucrose diet, mice were assigned to ASO study groups based on body weight and liver fat percentage, as
assessed by MRI. Pnpla3 mutant knock-in and wild-type mice were treated with either the control or Pnpla3 ASO (5 mg/kg/week administered by two subcutaneous injections per
week, n ¼ 9e12 mice/group) for 8 weeks. (A) Body weight gain before and after the ASO treatment. (B) Caloric intake before and after the ASO treatment. (C) Liver Pnpla3 mRNA
levels were measured by qPCR and normalized to the ribosomal protein large P0 (Rplp0). (D) Levels of the Pnpla3 protein in hepatic lipid droplets were measured by western
blotting. Plin2 was used as the loading control. Hepatic lipid droplets where puriﬁed by density gradient ultracentrifugation (see the Materials and Methods). (E,H) Representative
images of Oil Red O-stained liver sections after 8 weeks of ASO treatment (black scale bar represents 100 mm). Liver lipid levels were assessed by MRI after 6 weeks of ASO
treatment, and liver and plasma triglyceride levels were measured by biochemical assays when Pnpla3 mutant knock-in (FeG) and wild-type (IeJ) mice were euthanized after 8
weeks of ASO treatment. Values are presented as the mean  SEM. P values were calculated using 2-sided t-tests. Abbreviations: ASO: antisense oligonucleotide; MRI: magnetic
resonance imaging; Plin2: perilipin 2; Pnpla3: patatin-like phospholipase domain-containing 3; Rplp0: ribosomal protein large P0; AU: arbitrary unit; Ctrl: control. Mutant knock-in
mice are deﬁned as homozygotes for a methionine (M) at position 148 of the Pnpla3 protein, while wild-type littermates are homozygotes for an isoleucine (I) at the same position.
WT: wild-type; MUT: mutant.
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Figure 2: The Pnpla3 ASO treatment reduced liver Pnpla3 mRNA and protein levels and liver triglyceride levels in both Pnpla3 mutant knock-in mice and wild-type
littermates fed a NASH-inducing diet. A total of 17 male homozygous Pnpla3 148M/M (mutant) knock-in mice and 17 wild-type littermates were fed a NASH-inducing diet for 26
weeks. After 12 weeks of consumption of the NASH diet, mice were assigned to ASO study groups based on body weight. Pnpla3 mutant knock-in and wild-type mice were treated
with either control or Pnpla3 ASOs (5 mg/kg/week administered by two subcutaneous injections per week, n ¼ 8e9 mice/group) for 14 weeks. (A) Body weight was measured
throughout the experiment, while (B) caloric intake was measured before and after the ASO treatment. (C) Liver Pnpla3 mRNA levels were measured by qPCR and normalized to
Rplp0. (D) Levels of the Pnpla3 protein in hepatic lipid droplets were measured by western blotting. Plin2 was used as the loading control. Hepatic lipid droplets were puriﬁed by
density gradient ultracentrifugation (see the Materials and Methods). Plasma ALT, AST, and triglyceride levels and the liver triglyceride content in the Pnpla3 mutant knock-in (F,G)
and wild-type (I,J) mice were measured using biochemical assays. Values are presented as the mean  SEM. P values were calculated using 2-sided t-tests. Abbreviations: ASO:
antisense oligonucleotide; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Plin2: perilipin 2; Pnpla3: patatin-like phospholipase domain-containing 3; Rplp0:
ribosomal protein large P0; Ctrl: control; AU: arbitrary unit. Mutant knock-in mice are deﬁned as homozygotes for a methionine (M) at position 148 of the Pnpla3 protein, while wild-
type littermates are homozygotes for an isoleucine (I) at the same position. WT: wild-type; MUT: mutant.
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Figure 3: The Pnpla3 ASO treatment improved liver steatosis score, lobular inﬂammation score, NAFLD activity score, and ﬁbrosis stage in Pnpla3 mutant knock-in
mice and steatosis score and NAFLD activity score in wild-type mice fed a NASH-inducing diet. Homozygous Pnpla3 mutant knock-in and wild-type littermates were fed a
NASH-inducing diet for 26 weeks. After 12 weeks of consuming the NASH diet, Pnpla3 mutant knock-in and wild-type mice were treated with either control or Pnpla3 ASOs (5 mg/
kg/week administered by two subcutaneous injections per week, n ¼ 8e9 mice/group) for 14 weeks. Liver steatosis score, lobular inﬂammation score, NAS, and ﬁbrosis stage in
Pnpla3 mutant knock-in (A) and wild-type (B) mice. P values were calculated using ordinal regression analyses. Abbreviations: NAS: NAFLD activity score: Pnpla3: patatin-like
phospholipase domain-containing 3. Mutant knock-in mice are deﬁned as homozygotes for a methionine (M) at position 148 of the Pnpla3 protein, while wild-type littermates
are homozygotes for an isoleucine (I) at the same position. WT: wild-type; MUT: mutant.The Pnpla3 ASO treatment reduced the hepatic expression of the
collagen type I alpha 1 (Col1a1) mRNA in both Pnpla3 mutant knock-in
and wild-type mice (Figure 6A and B). However, the Pnpla3 ASO
treatment reduced the liver collagen, as measured by immunohisto-
chemistry (p ¼ 0.04), in only the Pnpla3 mutant knock-in mice
(Figure 6AeC). Although ASO treatment tended to decrease liver hy-
droxyproline levels, no signiﬁcant differences were observed
(Figure 6D and E). Interestingly, Pnpla3 ASO treatment speciﬁcally
reduced the liver Timp2 protein levels in Pnpla3 mutant knock-in mice
(p ¼ 0.007) but not in wild-type mice (Figure 7A). Pnpla3 ASO treat-
ment did not change the liver protein expression levels of Mmp2
(Figure 7B), Timp1 (Figure 7C), or Tgfbr2 (Figure 7D) in either geno-
type. Thus, Pnpla3 suppression speciﬁcally reduced the liver collagen
area and Timp2 protein levels in the Pnpla3 mutant mice.
4. DISCUSSION
The major novel ﬁndings of this study are that Pnpla3 silencing reduces
liver inﬂammation and ﬁbrosis in mutant mice homozygous for the
Pnpla3 148M sequence variant demonstrating that a PNPLA3 ASO
therapy can have beneﬁcial effects on the entire spectrum of NAFLD.
In our previous genetic association study in humans, the PNPLA3
rs2294918 sequence variant, a variant associated with lower hepatic
PNPLA3 expression, blunted the deleterious effect of the PNPLA3
148M mutant protein in subjects carrying this variant [23]. In addition,
the HSD17B13 rs72613567 sequence variant is associated with
reduced PNPLA3 mRNA expression and a decreased risk of liver injuryMOLECULAR METABOLISM 22 (2019) 49e61  2019 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comin subjects carrying the PNPLA3 148M mutant protein [24]. Therefore,
we hypothesized that suppression of the synthesis of this protein may
be beneﬁcial in homozygous carriers of the deleterious 148M protein.
We generated knock-in mice homozygous for the Pnpla3 mutant
(148 M/M) protein by replacing the isoleucine codon with a methionine
codon in amino acid position 148 of the mouse Pnpla3 gene. First, we
stimulated hepatic de novo lipogenesis by feeding mice a high-sucrose
diet to assess the impact of Pnpla3 silencing on moderate hepatic fat
accumulation. To compare data with those previously reported by
Smagris et al. [18], in this experiment, we used female mice and
found, consistently with their study, that Pnpla3 mutant knock-in mice
had higher liver fat content than the wild-type littermates [18]. Pnpla3
suppression speciﬁcally resulted in a 25% reduction in hepatic stea-
tosis in Pnpla3 mutant knock-in mice, whereas hepatic fat accumu-
lation was not affected by the treatment in wild-type littermates.
To investigate whether Pnpla3 silencing also ameliorated hepatic
inﬂammation and ﬁbrosis, we next fed male mice a NASH-inducing
diet [28,29] (high fructose, fat and cholesterol). This diet-induced
NASH model has already been proven useful to recapitulate the
beneﬁcial effects of compounds used in clinical trials for NASH on liver
fat accumulation, inﬂammation and ﬁbrosis [30]. The NASH diet
resulted in an approximately 5-fold higher liver fat content (up to one-
third of the total liver weight) as compared to the high-sucrose diet.
The lack of differences in liver fat content, inﬂammation, and ﬁbrosis
between Pnpla3 mutant knock-in mice and wild-type mice on the
NASH diet may due to; a) the very high amounts of calories and fat in
the diet, which overrode the effect of the genotype, b) the more severecess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 55
Figure 4: The Pnpla3 ASO treatment reduced liver steatosis, lipogenesis, and monounsaturated fatty acids in lipid droplets in Pnpla3 mutant knock-in mice and wild-
type littermates fed a NASH-inducing diet. Homozygous Pnpla3 mutant knock-in and littermate wild-type mice were fed a NASH-inducing diet for 26 weeks. After 12 weeks of
feeding on the NASH diet, Pnpla3 mutant knock-in and wild-type mice were treated with either control or Pnpla3 ASOs (5 mg/kg/week administered by two subcutaneous injections
per week, n ¼ 8e9 mice/group) for 14 weeks. (A) Representative images of Oil Red O-stained liver sections (black scale bar represents 100 mm). Liver mRNA expression levels of
Acc1 and Scd1 in Pnpla3 mutant knock-in (B) and wild-type (C) mice. Liver lipid droplet fatty acid composition in Pnpla3 mutant knock-in (D) and wild-type (E) mice. Values are
presented as the mean  SEM. P values were calculated using 2-sided t-tests. Abbreviations: Acc1: acetyl-CoA carboxylase 1; ASO: antisense oligonucleotide; Ctrl: control; MUFA:
monounsaturated fatty acid; Pnpla3: patatin-like phospholipase domain-containing 3; PUFA: polyunsaturated fatty acid; Rplp0: ribosomal protein large P0; Scd1: stearoyl-CoA
desaturase 1; SFA: saturated fatty acid. Mutant knock-in mice are deﬁned as homozygotes for a methionine (M) at position 148 of the Pnpla3 protein, while wild-type
littermates are homozygotes for an isoleucine (I) at the same position. WT: wild-type; MUT: mutant.
Table 1 e Composition of triglycerides in isolated hepatic lipid droplets
from mutant knock-in (MUT) and wild-type (WT) mice measured by
lipidomic analyses.
MUT WT
CTR ASO P value CTR ASO P value
MUFA 63 (0.47) 58 (0.43) 6.1  105 64 (0.39) 57 (0.58) 7.6  106
16:1 10 (0.22) 7 (0.35) 2.4  104 11 (0.17) 7 (0.13) 1.0  109
18:1 53 (0.46) 52 (0.21) 0.034 54 (0.52) 51 (0.53) 0.001
PUFA 14 (0.29) 17 (0.50) 1.1  105 12 (0.38) 17 (0.48) 1.3  106
18:2 11 (0.42) 13 (0.48) 0.007 11 (0.35) 13 (0.49) 0.006
20:3 0.78 (0.03) 1.08 (0.05) 1.3  104 0.53 (0.04) 1.01 (0.03) 3.3  105
20:4 0.68 (0.02) 1.04 (0.03) 2.6  107 0.31 (0.02) 1.09 (0.03) 1.2  107
22:5 0.32 (0.05) 0.95 (0.05) 2.6  105 0.07 (0.01) 0.90 (0.03) 9.1  109
22:6 0.74 (0.17) 1.06 (0.09) 0.048 0.17 (0.01) 0.96 (0.03) 1.4  109
SFA 24 (0.39) 25 (0.57) 0.999 24 (0.72) 26 (0.63) 0.141
14:0 0.47 (0.04) 0.41 (0.03) 0.275 0.46 (0.02) 0.40 (0.03) 0.122
16:0 22 (0.38) 22 (0.51) 0.693 22 (0.67) 24 (0.59) 0.093
18:0 1.3 (0.03) 1.8 (0.08) 4  104 1.2 (0.06) 1.8 (0.06) 9  105
Data are presented as mean (SEM). P values are calculated by t test and adjusted for
multiple testing by Bonferroni. Individuals fatty acids are denoted as number of carbon
and of double bonds.
Abbreviations: MUFA: Monounsaturated fatty acid; PUFA: Polyunsaturated fatty acid;
SFA: Saturated fatty acid.
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liver fat in the Pnpla3 mutant knock-in mice, or c) a lack of statistical
power to detect such differences. In addition, due to our study design,
we cannot rule out an interaction between gender and diet in deter-
mining liver fat content.
In our study, Pnpla3 silencing effectively reduced the liver fat and
circulating ALT levels in both genotypes. This result is consistent with
previous data obtained from wild-type rats fed a high-fat diet, where
suppression of wild-type Pnpla3 by an unconjugated 20-O-methox-
yethylribose (MOE) Pnpla3 ASO resulted in a reduction in the hepatic fat
due to lower lipogenesis [25]. A likely explanation for the reduced liver
steatosis in our model is also a reduced lipogenesis, as supported by
lower expression of the Acc1 and Scd1 mRNAs.
To understand changes in the composition of fatty acids we puriﬁed
hepatic lipid droplets from the mice and examined the triglyceride
plethora by lipidomic analyses. Overall, the changes observed after
ASO treatment were the same in the mutant as compared to the wild-
type mice. Speciﬁcally, we observed lower levels of MUFAs in
particular palmitoleic acid after Pnpla3 ASO treatment irrespective of
the genotype. The lower abundance of palmitoleic acid is consistent
with the lower levels of Scd1, the main enzyme responsible for
desaturating fatty acids during lipogenesis. We found relatively higherhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: The Pnpla3 ASO treatment reduced plasma haptoglobin levels, liver macrophage content, and Mcp1 levels in Pnpla3 mutant knock-in mice fed a NASH-
inducing diet. Homozygous Pnpla3 mutant knock-in and wild-type littermates were fed a NASH-inducing diet for 26 weeks. After 12 weeks of consuming the NASH diet, Pnpla3
mutant knock-in and wild-type mice were treated with either control or Pnpla3 ASOs (5 mg/kg/week administered by two subcutaneous injections per week, n ¼ 8e9 mice/group)
for 14 weeks. Plasma haptoglobin levels and liver macrophage contents (as determined by Mac2 staining) in Pnpla3 mutant knock-in (A) and wild-type (B) mice. (C) Representative
images of Mac2-stained liver sections (black scale bar represents 100 mm). Liver protein levels of Mcp1 (D), Il1b (E), Il6 (F), Tnfa (G), and aSma (H) measured with western blot
analyses. Values are presented as the mean  SEM. P values were calculated using 2-sided t-tests. Abbreviations: aSma: alpha-smooth muscle actin; ASO: antisense oligo-
nucleotide; Ctrl: control; Il: Interleukin; Mac2: macrophage antigen 2. Mcp1: monocyte chemoattractant protein 1; Pnpla3: patatin-like phospholipase domain-containing 3; Tnfa:
tumor necrosis factor alpha. Mutant knock-in mice are deﬁned as homozygotes for a methionine (M) at position 148 of the Pnpla3 protein, while wild-type littermates are
homozygotes for an isoleucine (I) at the same position. WT: wild-type; MUT: mutant.
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Figure 6: The Pnpla3 ASO treatment reduced liver ﬁbrosis in Pnpla3 mutant knock-in mice fed a NASH-inducing diet. Homozygous Pnpla3 mutant knock-in and wild-
type littermates were fed a NASH-inducing diet for 26 weeks. After 12 weeks of feeding on the NASH diet, Pnpla3 mutant knock-in and wild-type mice were treated with either
control or Pnpla3 ASOs (5 mg/kg/week administered by two subcutaneous injections per week, n ¼ 8e9 mice/group) for 14 weeks. Liver Col1a1 mRNA and protein
(immunohistochemistry) levels in Pnpla3 mutant knock-in (A) and wild-type mice (B). (C) Representative images of collagen immunohistochemistry in liver sections (black scale
bar represents 100 mm). Liver hydroxyproline levels in Pnpla3 mutant knock-in (D) and wild-type mice (E). Values are presented as the mean  SEM. P values were calculated
using 2-sided t-tests. Abbreviations: ASO: antisense oligonucleotide; Col1a1: collagen type I alpha 1 chain; Ctrl: control; Rplp0: ribosomal protein large P0. Mutant knock-in mice
are deﬁned as homozygotes for a methionine (M) at position 148 of the Pnpla3 protein, while wild-type littermates are homozygotes for an isoleucine (I) at the same position.
WT: wild-type; MUT: mutant.
Original Articlelevels of PUFAs in lipid droplets after Pnpla3 ASO treatment irre-
spective of the genotype. This may be due to either a redistribution of
PUFAs channeled into the triglycerides in the tissue, or directly related
to the decrease in MUFAs. A previous study on the lipidome of puriﬁed
hepatic lipid droplets suggests a potential novel enzymatic activity of
Pnpla3 acquired speciﬁcally by the mutant protein [32]. Results of our
analyses are in line with this hypothesis. A previous study on the liver
lipidome of humans indicate that PNPLA3 148M mutant allele carriers
have more polyunsaturated triacylglycerols than wild-type allele car-
riers [33]. However, in a recent study, when high liver fat to normal
liver fat groups were compared, PNPLA3 wild-type and mutant allele
carriers showed similar lipid changes although wild-type carriers
presented with a higher proportion of speciﬁc diacylglycerols that may
explain the dissociation between liver fat and insulin resistance in
PNPLA3 148M mutant allele carriers [34]. Noteworthy, these human
lipidomic studies were performed in whole liver specimens (as
opposed to puriﬁed lipid droplets in this study) making results a bit
difﬁcult to compare.
We found lower circulating haptoglobin levels, liver macrophage
content, and moderately reduced lobular inﬂammation after Pnpla3
ASO treatment in the Pnpla3mutant knock-in mice, but not in the wild-
type mice. Haptoglobin is an acute phase protein produced by the liver58 MOLECULAR METABOLISM 22 (2019) 49e61  2019 The Authors. Published by Elsevier GmbH. Tand also by the adipose tissue [35] where we also observed a sup-
pression of Pnpla3 after treatment. Therefore, we cannot rule out that
plasma haptoglobin levels were inﬂuenced by reduced inﬂammation in
the adipose tissue. However, plasma haptoglobin correlates to the
degree of adiposity [36] and the Pnpla3 ASO treatment did not affect
body weight or adiposity. Pnpla3 ASO treatment speciﬁcally reduced
liver Mcp1 levels in the Pnpla3 mutant knock-in mice, but not in the
wild-type mice. Mcp1 and its receptor CeC chemochine receptor-2
(Ccr2) play a pivotal role in recruiting monocytes/macrophages to
sites of inﬂammation in the liver [37,38]. In addition, haptoglobin can
attract monocytes/macrophages in part through its interaction with
Ccr2 [35]. Genetic deletion of Mcp1 or Ccr2 and Ccr2 inhibition protect
from liver inﬂammation [37,39]. Thus, Pnpla3 silencing may decrease
liver inﬂammation speciﬁcally through down-regulation of liver Mcp1 in
Pnpla3 mutant knock-in mice.
When we examined liver ﬁbrosis, we found a consistent Pnpla3 ASO-
mediated reduction in both the liver collagen expression and ﬁbrosis
severity in the Pnpla3 mutant knock-in mice but not in the wild-type
mice. We also found lower hepatic Timp2 protein levels present only
in the mutant knock-in mice. TIMP2 expression levels are elevated in
activated human hepatic stellate cells [40] and in ﬁbrotic rat livers [41].
Moreover, TIMP2 directly inhibits the collagenolytic activity of MMP2his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: The Pnpla3 ASO treatment reduced liver Timp2 protein levels in Pnpla3 mutant knock-in mice fed a NASH-inducing diet. Homozygous Pnpla3 mutant knock-in
and wild-type littermates were fed a NASH-inducing diet for 26 weeks. After 12 weeks of feeding on the NASH diet, Pnpla3 mutant knock-in and wild-type mice were treated with
either control or Pnpla3 ASOs (5 mg/kg/week administered by two subcutaneous injections per week, n ¼ 8e9 mice/group) for 14 weeks. Liver protein levels of Timp2 (A), Mmp2
(B), Timp1 (C), and Tgfbr2 (D) measured with western blot analyses. Values are presented as the mean  SEM. P values were calculated using 2-sided t-tests. Abbreviations: ASO:
antisense oligonucleotide; Mmp2: matrix metalloproteinase 2; Tgfbr2: transforming growth factor, beta receptor 2; Timp: tissue inhibitor of metalloproteinase. Mutant knock-in
mice are deﬁned as homozygotes for a methionine (M) at position 148 of the Pnpla3 protein, while wild-type littermates are homozygotes for an isoleucine (I) at the same position.
WT: wild-type; MUT: mutant.[42] which is increased in experimental models of ﬁbrosis and in
humans with chronic liver disease [43e47]. Finally, we have shown
in vitro and ex vivo that PNPLA3 has retinyl esters activity and the
mutant, predisposing to more severe ﬁbrosis, has higher secretion of
TIMP2 [48]. Thus, the speciﬁc reduction in liver ﬁbrosis in mutant mice
seems to be dependent on a higher collagenolytic activity mediated by
lower Timp2 secretion from hepatic stellate cells. Notably, Pnpla3
silencing in wild-type mice reduced the hepatic mRNA levels of the
Col1a1 and tended to reduce the liver collagen content and Timp2
expression levels. Based on these data, a study with a longer duration
and more animals might reveal a beneﬁcial effect of the Pnpla3 ASO
treatment also in the wild-type mice.
Taken all this together, we show a speciﬁc effect in reducing liver
inﬂammation and ﬁbrosis after suppression of Pnpla3 speciﬁcally in
the mutant knock-in mice. This effect could be due to: a) decreased
inﬂammation caused by lower levels of chemokine attracting inﬂam-
matory cells, b) higher collagen breakdown resulting from the inhibition
of a tissue metalloproteinase family member, and c) a direct beneﬁcial
effect of reducing the accumulation of the potentially toxic mutant
protein on lipid droplets.
In terms of translation into human treatments, suppression of the
synthesis of the PNPLA3 protein may be beneﬁcial in patientsMOLECULAR METABOLISM 22 (2019) 49e61  2019 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.compresenting with NAFLD. Importantly, the suppression of this protein
would ameliorate liver inﬂammation and ﬁbrosis, the main variables
underlying the clinical outcomes, more markedly in individuals who are
homozygous for the PNPLA3 148M mutant protein. In addition, several
improvements were also seen in wild-type mice indicating that such a
therapy may also prove to be beneﬁcial in wild type allele carriers.
Currently, no approved drugs efﬁciently curing NAFLD or NASH are
available. However, several treatment options are currently being
evaluated in clinical trials [1,4,49]. Thus, a variety of pathway-speciﬁc
drugs designed to treat NAFLD and NASH will probably emerge in the
future. However, this preclinical study provides a proof of concept
evidence for a precision medicine approach as a treatment for NASH by
identifying a sub-population (PNPLA3 148M allele carriers) that may be
high responders to a PNPLA3 ASO therapy. Thus, this therapeutic
approach exploits a common innate genetic risk variant to ameliorate
the disease using delivery of a GalNAc3-conjugated PNPLA3 ASO to
liver cells.
In conclusion, we show that Pnpla3 silencing exerts a beneﬁcial
effect, more pronounced in the presence of the Pnpla3 148M mu-
tation, on liver fat accumulation, inﬂammation, and ﬁbrosis. Further
studies are needed to assess whether these ﬁndings will translate to
humans.cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 59
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